AbbVie’s Maviret Receives EC Approval for Acute Hepatitis C Virus Infection

Shots: The EC has approved Maviret (glecaprevir/pibrentasvir) for the treatment of acute hepatitis C virus (HCV) infection in pts (≥3yrs.) with compensated liver disease (with or without cirrhosis) Approval was based on the P-III (M20-350) trial assessing Maviret (QD, PO) in pts (≥12yrs.) with acute HCV infection, enrolling 286 treatment-naïve adults across 70 locations globally Trial…

ByRidhi RastogiJune 24, 2026

NEWS

Combotope Therapeutics and Boehringer Ingelheim Collaborate on Next-Generation Cancer Antibody Therapies

Shots: BI has entered into a strategic research collaboration with Combotope to leverage its SMART-Phage platform to produce highly tumor-selective antibodies for next-generation cancer therapies Combotope will discover tumor-selective, high-affinity antibodies against multiple BI oncology targets, while BI will hold global development & commercialization rights, and lead further R&D, manufacturing, & commercialization activities As per…

ByRidhi RastogiJune 24, 2026

NEWS

Spotlight Medical Gains CE Mark for myStage Dx as an AI-Based Prognostic Test for ER+/HER2- Early Breast Cancer

Shots: Spotlight Medical has received CE marking under the EU IVDR for myStage Dx, an AI-enabled prognostic test designed to support risk stratification in patients with ER+/HER2- early breast cancer Test analyzes digitized H&E-stained FFPE pathology slides alongside routine clinicopathological variables to generate a binary prognostic classification of Low Risk or Not Low Risk In…

ByRidhi RastogiJune 24, 2026

NEWS

Gilead’s Trodelvy Receives the EC Approval for 1L Metastatic TNBC Patients Ineligible for PD-1/PD-L1 Inhibitor Therapy

Shots: The EC has approved Trodelvy monotx. as a 1L therapy for the treatment of adults with unresectable or metastatic TNBC who are ineligible for PD-1/PD-L1 inhibitor therapy across all 30 EEA states Approval was backed by the P-III (ASCENT-03) trial showing a 38% reduced risk of disease progression or death in patients who are…

ByRidhi RastogiJune 24, 2026

NEWS

Abbisko Therapeutics Inks ~$1.9B Multi-Target R&D Deal with Eli Lilly

Shots: Abbisko Therapeutics has entered into a strategic research collaboration & license agreement with Eli Lilly to discover & develop novel therapeutics across multiple targets Abbisko will leverage its early-stage drug discovery platform, R&D ecosystem, & development expertise to conduct discovery & early-stage development of novel therapeutics against disease targets selected by Lilly As per…

ByRidhi RastogiJune 24, 2026

NEWS

Organon and Henlius Launch Bildyos and Tuzemty (Biosimilars, Prolia and Xgeva) in Canada

Shots: Organon & Henlius Biotech have reported availability of Bildyos (60mg/1mL) & Tuzemty (120mg/1.7mL), biosimilar versions of Prolia & Xgeva (denosumab), respectively, in Canada for all indications of reference products Under a 2022 agreement, Henlius granted Organon exclusive global commercialization rights, excl. China, for multiple biosimilars, incl. Bildyos & Tuzemty Denosumab is a mAb that works…

ByRidhi RastogiJune 23, 2026

NEWS

Arrowhead Pharmaceuticals Receives EC Approval for Redemplo to Treat Familial Chylomicronemia Syndrome

Shots: The EC has approved Redemplo as an adjunct to diet to reduce triglycerides (TGs) in adults with Familial Chylomicronemia Syndrome (FCS), backed by the P-III (PALISADE) trial assessing it (25 & 50mg, SC, Q3M) vs PBO in 75 FCS adults Trial met its 1 & all multiplicity-controlled key 2EPs. 25mg showed an 80% vs…

ByRidhi RastogiJune 23, 2026

NEWS

Sanofi Reports the EC Approval for Cenrifki (Tolebrutinib) to Treat SPMS without Relapses

Shots: The EC has approved Cenrifki (PO, QD) for the treatment of secondary progressive multiple sclerosis (SPMS) without relapses in the last 2yrs. Approval was backed by P-III (HERCULES) trial (vs PBO) in non-relapsing SPMS (nrSPMS) & supporting data from P-III (GEMINI 1 & 2) studies (vs teriflunomide) in relapsing MS, with HERCULES demonstrating delayed…

ByRidhi RastogiJune 23, 2026

NEWS

Nuvectis Expands Pipeline with ~ $1.46B Ex-China Licensing Deal for Two Late-Stage Assets from Haisco

Shots: Nuvectis has licensed exclusive ex-China rights to NXP100 (HSK39297; QD, PO), a Complement Factor B inhibitor, & NXP200 (HSK42360), a brain-penetrant paradox-breaker BRAF inhibitor from Haisco, transforming the company into a late-stage development player As per the deal, Haisco will receive ~$40M in upfront & near-term payments, plus up to $1.421B in development,…

ByRidhi RastogiJune 23, 2026

NEWS

Antengene Inks ~$1.96B Bispecific T-Cell Engager Deal with K2 Therapeutics

Shots: Antengene has licensed ATG-106, a preclinical CDH6×CD3 bispecific T-cell engager for solid tumors, to K2 Therapeutics & granted an option for exclusive rights to a second undisclosed bispecific TCE candidate, covering all global markets excl. Greater China As per the licensing deal, Antengene will receive $20M in upfront & near-term consideration, incl. cash &…

ByRidhi RastogiJune 23, 2026

Ridhi Rastogi

AbbVie’s Maviret Receives EC Approval for Acute Hepatitis C Virus Infection

Combotope Therapeutics and Boehringer Ingelheim Collaborate on Next-Generation Cancer Antibody Therapies

Spotlight Medical Gains CE Mark for myStage Dx as an AI-Based Prognostic Test for ER+/HER2- Early Breast Cancer

Gilead’s Trodelvy Receives the EC Approval for 1L Metastatic TNBC Patients Ineligible for PD-1/PD-L1 Inhibitor Therapy

Abbisko Therapeutics Inks ~$1.9B Multi-Target R&D Deal with Eli Lilly

Organon and Henlius Launch Bildyos and Tuzemty (Biosimilars, Prolia and Xgeva) in Canada

Arrowhead Pharmaceuticals Receives EC Approval for Redemplo to Treat Familial Chylomicronemia Syndrome

Sanofi Reports the EC Approval for Cenrifki (Tolebrutinib) to Treat SPMS without Relapses

Nuvectis Expands Pipeline with ~ $1.46B Ex-China Licensing Deal for Two Late-Stage Assets from Haisco

Antengene Inks ~$1.96B Bispecific T-Cell Engager Deal with K2 Therapeutics

Contact US

FOLLOW US